PET/CT
41
22
22
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
2.4%
1 terminated out of 41 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (41)
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
FAP-targeted PET/NIR in Lung Malignant Tumors
68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
PET-CT in Lymphoma Among the Eldery
Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
68Ga-XACP3 PET/CT in Prostate Cancer
PET/CT for Trop2 ADC Response Evaluation NSCLC
[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
68Ga-DOTA-hLAG-3 PET Imaging of LAG-3 Expression in Cancers
PET/CT for Trop2 ADC Response Evaluation Cancers
68Ga-MY6349 PET/CT in Solid Tumors
CXCR4-targeted PET/CT Imaging in Hematological Malignancies
68Ga-FAPI PET/CT in Malignant Tumors
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
Added Value of PET/CT in Assessment of Hepatocellular Malignancy Post Radiofrequency Ablation
Integrin αvβ6-targeted PET in Malignant Tumors
Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy
PET/CT Follow up for Head and Neck Squamous Cell Carcinoma
18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma
Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer